Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Lacosamide

An antiepileptic of the functionalised amino acid class, discovered at the University of Houston in the 1990s and approved in 2008 in Europe and the United States for focal seizures. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It acts on neuronal sodium channels in an unusual way: it enhances their 'slow' inactivation while leaving the fast one untouched. Its activity comes from just one of its two enantiomers, the R form.

LacosamideGo to the active ingredient →
LacosamideActive ingredientLacosamideCat. No. P-L003-001CAS 175481-36-4
(S)-LacosamidePharmacopoeial impurity(S)-LacosamideCat. No. P-L003-005CAS 175481-37-5
Lacosamide-d3Isotopically labelledLacosamide-d3Cat. No. P-L003-026CAS 1217689-95-6
Lac2-ibcaImpurityLac2-ibcaCat. No. P-L003-058CAS 1325220-60-7

EDQM standards 5

The official European Pharmacopoeia standards for this family.

Reference substanceLacosamide CRSEDQM code Y0001982Family Lacosamide

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.